(Information sent by the signatory company)

– Dragonfly Therapeutics, Inc. announces a clinical collaboration to evaluate DF9001, an EGFR-targeting TriNKET®, in combination with KEYTRUDA® (pembrolizumab) in patients with solid tumors

– DF9001 is currently being evaluated as monotherapy for the treatment of non-small cell lung cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck. The clinical trial collaboration will focus on evaluation of the investigational combination in second-line renal cell carcinoma and second-line head and neck squamous cell carcinoma.

WALTHAM, Mass., May 21, 2024 /PRNewswire/ — Dragonfly Therapeutics, Inc, a clinical-stage biotechnology company developing novel immunotherapies, today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the United States). United States and Canada), to evaluate DF9001, Dragonfly’s EGFR immunoinhibitor, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors that express EGFR.

“Merck, a trusted leader in drug development, has been a wonderful collaborator with Dragonfly since we signed our first collaboration agreement in 2018,” said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. “We are pleased to enter into this agreement with Merck for our ongoing investigational Phase 1 trial with DF9001. In preclinical models, DF9001 activates multiple immune effector cells to drive antitumor activity and induces PD-L1 expression on tumor cells, sensitizing cold tumors to checkpoint inhibitors. We are confident that DF9001, in combination with KEYTRUDA, will deliver potent antitumor activity across a broad range of indications and look forward to further accelerating progress in the clinic to benefit patients. they need it”.

Dragonfly is the study sponsor and the first patients are expected to receive DF9001 in combination with pembrolizumab in the fourth quarter of 2024. Clinical trial sites are currently open for monotherapy dosing in the United States, and sites are expected to open additional trials in North America and Europe in 2024. More information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT 05597839.

KEYTRUDA® is a registered trademark of Merck Sharp

About DF9001 DF9001 is an investigational first-in-class multispecific drug candidate that targets EGFR and potently redirects natural killer (NK) cells, gamma-delta T cells, and CD8 T cells through activation of NKG2D receptors. and CD16. DF9001 was discovered and developed using Dragonfly’s TriNKET® platform. DF9001 is being evaluated in adult patients for the treatment of advanced EGFR-positive solid tumors. DF9001 has the potential to boost antitumor immunity in patients who do not qualify for or respond adequately to current therapies. DF9001 is the second proprietary drug candidate in a line of TriNKETs that Dragonfly is developing to address large unmet patient needs across a broad range of disease areas.

About DragonflyDragonfly Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies that harness the body’s immune system to deliver innovative treatments to patients. In addition to a suite of advanced clinical-stage programs, Dragonfly has an extensive pipeline of proprietary preclinical candidates discovered through its proprietary platforms advancing to the clinical stage, as well as productive collaborations with AbbVie, Bristol Myers Squibb, Gilead and Merck in a wide range of diseases.

For more information visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx

DRAGONFLY MEDIA CONTACT:Anne E. Deconinck | anne@dragonflytx.com

Logo – https://mma.prnewswire.com/media/390962/…

View original content: https://www.prnewswire.com/news-releases/dragonfly-therapeutics-inc-anuncia-una-colaboracion-clinica-para-evaluar-df9001-302151384.html